Back to School: How biopharma can reboot drug development. Access exclusive analysis here

2nd generation PIs

Of the four HIV protease inhibitors on the market, many have shortcomings in key areas of convenience, pharmacokinetics or tolerability. Vertex Pharmaceuticals Inc. and Abbott Laboratories believe that their second generation inhibitors, Agenerase amprenavir and ABT-378, have characteristics that will make their compounds the protease inhibitors of choice in future HIV cocktail

Read the full 527 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers